Legal Circumvention
Legal Circumvention
Molecular switches provide a route around existing gene patents
5 Big Drug Companies Face R&D Drought
5 Big Drug Companies Face R&D Drought
Five of the world’s biggest drug companies do not have any potential billion-dollar drugs in late-stage development, highlighting the industry’s current poor R&D productivity, according to a report released on Wednesday.
Informatics Moves to the Head of the Class
Informatics Moves to the Head of the Class
The race is on to increase the quantity and quality of bio-IT training programs as government and academia bet the need will be great. Will the job market back that up?
Nanopharmaceuticals Open Up Brand New Field Of Study
Nanopharmaceuticals Open Up Brand New Field Of Study
Drug-binding molecules tiny enough to travel through the body’s smallest capillaries may provide a way to spare the heart and other organs from the toxic effects of drug overdose.
Networked Pharma
Networked Pharma
The pharmaceutical industry is experiencing a deepening productivity crisis. The industry’s preferred escape mechanism from this predicament has been to increase investment in current business activities – primarily R&D and sales – to sustain productivity levels or, ideally, to exploit economies of scale. This has been implemented through organic growth of critical resources and/or M&A. The fact that productivity continues to decline after a decade of vigorous growth in investment levels, and against a background of increasing company size, bears testament to the fallibility of this strategy.
Get updates by email
Editor
Yali Friedman lives in Washington, DC and is author of Building Biotechnology and other books; founder of DrugPatentWatch; and chief editor of the Journal of Commercial Biotechnology.
and Share
Reading
Translator
© Copyright - BiotechBlog — A thinkBiotech product
Recent Comments